Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 in Rheumatic Heart Disease Surgery
NCT05487469Unknown
- Sponsor
- Nanjing Medical University
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of thymosin alpha 1 in rheumatic heart disease (RHD) (2 arms), sponsored by Nanjing Medical University. Primary endpoint: The highest Sequential Organ Failure Assessment (SOFA) score at 5 days. Status: unknown.
02
Drugs
thymosin alpha 1
03
Conditions
rheumatic heart disease (RHD)
Beyond the preview
Go deeper on NCT05487469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487469.